Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 4
2009 2
2010 6
2011 5
2012 14
2013 6
2014 3
2015 8
2016 7
2017 9
2018 12
2019 18
2020 14
2021 12
2022 19
2023 16
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Results by year

Filters applied: . Clear all
Page 1
IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognition.
Borch A, Carri I, Reynisson B, Alvarez HMG, Munk KK, Montemurro A, Kristensen NP, Tvingsholm SA, Holm JS, Heeke C, Moss KH, Hansen UK, Schaap-Johansen AL, Bagger FO, de Lima VAB, Rohrberg KS, Funt SA, Donia M, Svane IM, Lassen U, Barra C, Nielsen M, Hadrup SR. Borch A, et al. Among authors: donia m. Front Immunol. 2024 Apr 3;15:1360281. doi: 10.3389/fimmu.2024.1360281. eCollection 2024. Front Immunol. 2024. PMID: 38633261 Free PMC article.
Molecular patterns of resistance to immune checkpoint blockade in melanoma.
Lauss M, Phung B, Borch TH, Harbst K, Kaminska K, Ebbesson A, Hedenfalk I, Yuan J, Nielsen K, Ingvar C, Carneiro A, Isaksson K, Pietras K, Svane IM, Donia M, Jönsson G. Lauss M, et al. Among authors: donia m. Nat Commun. 2024 Apr 9;15(1):3075. doi: 10.1038/s41467-024-47425-y. Nat Commun. 2024. PMID: 38594286 Free PMC article.
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.
Ten Ham RMT, Rohaan MW, Jedema I, Kessels R, Stegeman W, Scheepmaker W, Nuijen B, Nijenhuis C, Lindenberg M, Borch TH, Monberg T, Donia M, Marie Svane I, van Harten W, Haanen J, Retel VP. Ten Ham RMT, et al. Among authors: donia m. J Immunother Cancer. 2024 Mar 26;12(3):e008372. doi: 10.1136/jitc-2023-008372. J Immunother Cancer. 2024. PMID: 38531663 Free PMC article. Clinical Trial.
Biomarkers for response to TIL therapy: a comprehensive review.
Albarrán Fernández V, Ballestín Martínez P, Stoltenborg Granhøj J, Borch TH, Donia M, Marie Svane I. Albarrán Fernández V, et al. Among authors: donia m. J Immunother Cancer. 2024 Mar 13;12(3):e008640. doi: 10.1136/jitc-2023-008640. J Immunother Cancer. 2024. PMID: 38485186 Free PMC article. Review.
Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression.
Homburg S, Christensen CB, Pedersen M, Sørensen SG, Donia M, Svane IM, Hendel HW, Ellebaek E. Homburg S, et al. Among authors: donia m. Cancers (Basel). 2024 Feb 27;16(5):964. doi: 10.3390/cancers16050964. Cancers (Basel). 2024. PMID: 38473325 Free PMC article.
Dissecting tumor microenvironment heterogeneity in syngeneic mouse models: insights on cancer-associated fibroblast phenotypes shaped by infiltrating T cells.
Carretta M, Thorseth ML, Schina A, Agardy DA, Johansen AZ, Baker KJ, Khan S, Rømer AMA, Fjæstad KY, Linder H, Kuczek DE, Donia M, Grøntved L, Madsen DH. Carretta M, et al. Among authors: donia m. Front Immunol. 2024 Jan 8;14:1320614. doi: 10.3389/fimmu.2023.1320614. eCollection 2023. Front Immunol. 2024. PMID: 38259467 Free PMC article.
147 results